Evidence map›Paper›PMID 35960159›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2022

Taking the Road Less Traveled: Following Molecular Trail Markers.

Ana C Veneziani, Amit M Oza

Abstract readComment
PubMed Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Heterogeneity and treatment landscape of ovarian carcinoma.Nature reviews. Clinical oncology · 2023
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Ana C VenezianiPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.ORCID 0000-0003-3980-034X
Amit M OzaPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.ORCID 0000-0002-9510-8641

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Targeted therapy largely remains an unmet therapeutic need for low-grade serous ovarian carcinomas. However, recent advances in molecular characterization are beginning to change the landscape. A recent article highlights the association of genetic alterations with clinical outcomes, widening the scope of novel targeted therapies. See related article by Manning-Geist et al., p. 4456.

Indexed as

Cystadenocarcinoma, SerousOvarian NeoplasmsPeritoneal NeoplasmsFemaleHumansMutation

Identifiers

PMID35960159

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.